Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists

BACKGROUND: Assessment of programmed cell death-ligand 1 (PD-L1) immunohistochemical staining is used for treatment decisions in non-small cell lung cancer (NSCLC) regarding use of PD-L1/programmed cell death protein 1 (PD-1) immunotherapy. The reliability of the PD-L1 22C3 pharmDx assay is critical...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Sunhee, Park, Hyung Kyu, Choi, Yoon-La, Jang, Se Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pathologists and the Korean Society for Cytopathology 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877442/
https://www.ncbi.nlm.nih.gov/pubmed/31656061
http://dx.doi.org/10.4132/jptm.2019.09.29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877442/
https://www.ncbi.nlm.nih.gov/pubmed/31656061
http://dx.doi.org/10.4132/jptm.2019.09.29

Ejemplares similares